Driving safely into solid tumors with CAR exosomes

CAR T-derived exosomes as safer, more efficacious CAR T cell alternative for solid tumors

Therapeutic exosomes derived from CAR T cells could avoid the cytotoxic side effects of the engineered cells and overcome barriers in the tumor microenvironment that limit the cells’ efficacy.

The obstacles to deploying CAR T cell therapies against solid tumors include immunosuppressive microenvironments and, across all

Read the full 450 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE